A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)
A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)
This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine
This study used a single-cohort, 3-treatment arm, randomized, double-blind study design in adult patients with episodic migraine. The subjects were randomized to receive either erenumab or placebo in a 2:3:3 ratio (erenumab 140 mg: erenumab 70 mg: placebo). A screening period of 2 weeks was used to assess initial eligibility, followed by a 4-week baseline period. After randomization/Day 1, visits occurred at four week intervals until Week 12, which was the End of Treatment. The final visit, Last Patient Last Visit was a Safety Follow-Up visit, which occurred 12 weeks later, at Week 24.
Key inclusion criteria:
Key exclusion criteria:
CABA, Buenos Aires C1056ABJ, Argentina
CABA, Buenos Aires C1181ACH, Argentina
CABA, Buenos Aires C1428AQK, Argentina
Ciudad Autonoma de Bs As, C1128AAF, Argentina
El Chouf, LBN 1503201002, Lebanon
Taichung County, Taiwan